If you spend any time in health, fitness, or weight loss circles online, you have almost certainly heard about GLP-1 medications. The conversation is everywhere — from clinical research to social media to your doctor's office. But the substance behind the noise is often thin. This article is a straightforward educational overview of what GLP-1-based medications actually are, how the three most talked-about compounds differ, and why the science behind them matters for anyone trying to understand this space clearly.

What Is GLP-1?

GLP-1 stands for glucagon-like peptide-1. It is a hormone your body produces naturally in the gut — specifically in the small intestine — in response to eating. Every time you consume a meal, GLP-1 is released as part of your body's coordinated response to incoming nutrients.

This hormone does several important things simultaneously. It signals the brain to reduce appetite and increase feelings of fullness. It prompts the pancreas to release insulin in response to rising blood glucose. It slows gastric emptying, which blunts blood sugar spikes after meals. And it suppresses glucagon, the hormone responsible for raising blood sugar between meals.

In short, GLP-1 is a meaningful player in appetite regulation, blood sugar control, and the broader coordination of energy balance. GLP-1-based medications are engineered to activate these same receptor pathways — but in a more sustained, amplified way than the body's own hormone allows. Natural GLP-1 degrades within minutes. These medications are designed to last days or a full week.

"GLP-1 is not a foreign concept introduced by pharmaceutical companies — it is a hormone your body already produces. These medications work by amplifying a biological system that already exists."

Three Compounds Worth Understanding

The GLP-1 medication landscape is evolving quickly, and the three compounds generating the most attention right now each work a little differently. Understanding those differences is the clearest way to make sense of why this space is moving so fast.

Semaglutide

Semaglutide is an FDA-approved GLP-1 receptor agonist. It works by selectively binding to and activating GLP-1 receptors throughout the body, producing the appetite suppression, insulin modulation, and gastric effects described above. It is prescribed under the brand names Ozempic (for type 2 diabetes management) and Wegovy (for chronic weight management at a higher dose). Both are administered as weekly subcutaneous injections. Clinical trials for semaglutide at weight management doses have shown average reductions of roughly 15–17% of body weight over approximately 68 weeks.

Tirzepatide

Tirzepatide is an FDA-approved dual receptor agonist — meaning it activates two separate receptor systems rather than one. It targets both GLP-1 receptors and GIP receptors. GIP, or glucose-dependent insulinotropic polypeptide, is another incretin hormone involved in insulin release and fat metabolism. By acting on both pathways simultaneously, tirzepatide produces a broader hormonal response than semaglutide alone. It is prescribed as Mounjaro for type 2 diabetes and Zepbound for weight management. Clinical trials have shown average weight reductions approaching 20–22% in certain populations — higher than semaglutide on average, though individual responses vary.

Retatrutide

Retatrutide is an investigational triple receptor agonist currently in clinical trials. It is not FDA approved, and it is not available as a standard prescribed medication. It acts on three receptor pathways simultaneously: GLP-1, GIP, and glucagon receptors. The addition of glucagon receptor activity is what distinguishes retatrutide from both semaglutide and tirzepatide — glucagon plays a direct role in energy expenditure and fat mobilization, which is why researchers are studying this compound with significant interest. Early-phase trial data has been compelling, but retatrutide should be understood as an emerging investigational therapy, not an established clinical option.

"Retatrutide is not FDA approved and is not currently available as a standard treatment. It is an investigational compound in active clinical development. Including it here is purely educational — to help people understand where the science is heading."

Why the Receptor Differences Matter

It can be tempting to treat these three compounds as variations of the same thing. They are not.

Semaglutide activates one receptor system. Tirzepatide activates two. Retatrutide, if approved, would activate three. Each layer of receptor activity adds a distinct physiological effect — and that is part of why clinical outcomes have trended upward with each more complex compound. It is also why the research conversation keeps evolving. The science is not finished. These are not the last medications in this class.

What this means practically is that GLP-1, GIP, and glucagon receptor activity each contribute something different to the overall effect on appetite, insulin regulation, energy expenditure, and fat metabolism. The more precisely a compound can target multiple pathways simultaneously, the broader its potential impact — which is exactly what researchers are trying to understand with compounds like retatrutide.

The Bottom Line

These are not all the same drug with different names. They are not magic, and they are not without nuance. Semaglutide and tirzepatide are established, FDA-approved medications with meaningful clinical track records. Retatrutide is a genuinely interesting investigational compound that may eventually expand what is possible in this space — but it is not there yet.

Understanding the receptor biology is worth the effort. It helps cut through the noise, gives you a clearer lens for evaluating new information as it emerges, and puts the conversation in better context than most of what you will find online. The next articles in this series cover who these medications are actually designed for — and what most people consistently misunderstand about using them well.